chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe acute dizziness, vertigo, nausea, vomiting. Slow improvement with meclazine, bedrest, complete cessation of all function for a week, followed by ongoing decrease in functional activity ongoing currently due to brain "fog",  headache, excessive fatigue, sleepiness, memory deficits.
He woke up with a painful arm from the vaccine. He complained of feeling dizzy and nauseous and then "blacked out."   It was determined to be a vasovagal reaction from the pain.
This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm was a tad bit sore), DIZZINESS (real dizzy), VISION BLURRED (eyes were blurry) and DYSSTASIA (hardly stand up) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination. Concurrent medical conditions included Type 2 diabetes mellitus (Type-II Diabetic). On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-May-2021, the patient experienced PAIN IN EXTREMITY (arm was a tad bit sore). On 12-May-2021, the patient experienced DIZZINESS (real dizzy), VISION BLURRED (eyes were blurry) and DYSSTASIA (hardly stand up). On 12-May-2021, VISION BLURRED (eyes were blurry) and DYSSTASIA (hardly stand up) had resolved. At the time of the report, PAIN IN EXTREMITY (arm was a tad bit sore) had resolved and DIZZINESS (real dizzy) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-May-2021, Blood test: normal (normal) normal. On 04-May-2021, Glycosylated haemoglobin: normal (normal) normal. On 04-May-2021, Metabolic function test: normal (normal) normal. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medicines usage was not provided by the reporter. No Treatment medicines were reported
About an hour and a half after the shot, my arm started tingling, my heart began to beat quickly, my face and throat started to swell, and I had difficulty breathing.
Hives within 24 hours of receiving DTAP, IPV, MMR (sister also with hives received DTAP, IPV from same lot #'s).
Seizure like activity; shaking, foaming at mouth, eyes rolling - then fainted; recovered w/in 45 seconds - afterwards - alert, stable vitals.
Numbness, tingling, and weakness in left finger tips.  Worst in middle finger but also present in index and ring finger.  Upper left arm pain at injection site, occurring at night time, has occurred the past week.
Massive LAD Heart attack on 4/24/2021 ten days following 2nd dose very sudden with no pre-existing signs
many people experienced vertigo; This case was reported by a consumer and described the occurrence of vertigo in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patients received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced vertigo. On an unknown date, the outcome of the vertigo was unknown.   It was unknown if the reporter considered the vertigo to be related to Shingrix.     Additional Information: GSK Receipt Date: 10-NOV-2022 Reporter's Comment: The reporter stated that, he/she found many people experienced vertigo after getting a Shingrix vaccine. Additional Supportive Information: The case had been linked to US2019035269 and US2019035262, reported by the same reporter, for a different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2019035262:Same reporter (reporter´s case) US-GLAXOSMITHKLINE-US2019035269:same reporter (friend of wife´s reporter´s case)
Extreme swollen leg with heat and redness turned into cellulitis requiring antibiotic therapy.
Fatigue; Chills; Body aches; This non-serious case was reported by a consumer via call center representative and described the occurrence of fatigue in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of covid-19 (received first dose about 2 years ago, refer case US2023098138).   On 16-JUL-2023, the patient received the 2nd dose of Shingrix (intramuscular, unknown deltoid). On 17-JUL-2023, 1 days after receiving Shingrix, the patient experienced fatigue (Verbatim: Fatigue), chills (Verbatim: Chills) and general body pain (Verbatim: Body aches). The outcome of the fatigue, chills and general body pain were not resolved.   It was unknown if the reporter considered the fatigue, chills and general body pain to be related to Shingrix.     It was unknown if the company considered the fatigue, chills and general body pain to be related to Shingrix.   Linked case(s) involving the same patient:  US2023098138   Additional Information: GSK Receipt Date: 17-JUL-2023 The reporter was the patient.  The patient did not receive the second dose within six months because she did not know she needed a second dose and because she developed COVID. The patient received second dose of Shingrix, and she had chills, fatigue and body aches. Nothing else was reported. The reporter consented to follow up.; Sender's Comments:  US-GSK-US2023098138:Same reporter, different dose
-right arm swollen, red, and hot to the touch (Fluad Quad given in R arm)  -pharmacy notified by RN at Facility on 10/9 around 2 pm
Within 24 hours post vax, the pt developed red marks on the arm, like a rash, at the injection site. This is one of two pts from this facility who experienced this event following receipt of vax.
Debilitating pain in the join of my left knee.; Unable to walk; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 24Aug2021 16:00 (Lot number: FC3181) at the age of 68 years as dose 2, single and administered in arm right, administration date 30Jul2021 16:00 (Lot number: FC7484) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Chronic obstructive pulmonary disease" (unspecified if ongoing); "Known allergies: Contrast Dye" (unspecified if ongoing), notes: Known allergies: Contrast dye. There were no concomitant medications. The following information was reported: ARTHRALGIA (non-serious) with onset 06Aug2021, outcome "not recovered", described as "Debilitating pain in the join of my left knee."; GAIT INABILITY (non-serious) with onset 06Aug2021, outcome "not recovered", described as "Unable to walk". Therapeutic measures were not taken as a result of arthralgia, gait inability.  Additional information: The patient had debilitating pain in the join of her left knee. Felt like a needle is being stabbed in the tissue part of knee joint. It was excruciating pain and she was unable to walk during episodes. She never had this before covid shot. The patient was administered COVID-19 vaccine in a pharmacy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medication within 2 weeks of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination nor was tested for COVID-19 since vaccination. The patient did not receive any treatment. The device date was 26Sep2021.  No follow-up attempts are possible. No further information is expected.
wasn't able to get the second dose; wasn't able to get the second dose; afterward got the shingles; This is a spontaneous report received from a contactable consumer(patient). This female patient of an unknown age received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) at single dose on 09Mar2021 via an unknown route for Covid-19 immunization. Medical history and concomitant drug were not provided. Patient got the first dose of the Pfizer BioNTech covid vaccine and afterward got the shingles.  So she wasn't able to get the second dose at 3 weeks because of the medicine she was taking for the shingles.  She saw doctor on Friday for a routine wellness check and she said to go ahead and get the second dose.  Outcome of shingles was unknown.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
I fainted at 7:00 am this morning. It was a syncope kind of faint like a vasovagal response. I have had this happen every 15 or so years. My mother has the same thing happen. Completely genetic. But I think it was triggered by this vaccine.
My first ever flu shot. Within 4 hours I became very nauseous, diarrhea the next day, low temperature the first night and next day, headache the next  day at night. Nauseous for 5 days, muscle weakness in legs for one day, felt out of breath when walking up stairs, very tired for 4 days. No pain. Overall I was feeling ill for 6 days. I was totally fine prior to the shot. Reached out to my primary to let her know what was going on. Let the pharmacist know my adverse events.
One of the vaccinators (a Medical Student) at an off-site mass vaccination event, administered the J & J Janssen COVID-19 vaccine to a teenager under the age of 18 years. The teen remained on site for 30 minutes after receiving the vaccine and experienced no ill effects.  An incident report was completed and signed by the medical student preceptor and the parent of the teen.  This report is being generated due to the vaccine being given off-label of manufacturers recommendations.
Fluzone HD was administered to 10-year-old patient on 12/6/22 around 3:00pm. Parents have been informed of the incident around 5:50pm and instructed to monitor for potential adverse effects. As of that discussion, there has been no reported symptoms.
Complex febrile seizure with status epilepticus with in 6 -8 hours of vaccination, + fever prior to seizure
Information has been received from a physician concerning an adult male patient in his thirties, who, a couple weeks ago (approximately July 2004) was vaccinated with a dose of varicella virus vaccine live.  The physician noted that on 07/16/2004 the patient developed about 20 varicella like lesions on his trunk.  There was no other information available regarding the lot number.  There was no treatment required for the varicella like lesions and no product quality complaint was reported.  Unspecified medical attention was sought.  Additional information has been requested.
Lost taste and smell (still don?t have it back) headache, sore throat, exhaustion, body aches
7/26/07 Within a few hours of receiving vaccine c/o tingling in her feet, awoke 7/27/07 - felt very sick, lightheaded - confused went to work, headaches, nauseous - took a nap after work and Sat/Sun rash on hands, feet and body.
Tinnitus since 2nd dose.  Never had before. Has not resolved as of 6/11/2021.
I had difficulty breathing through my nose, Sinus aches, jaw aches and lymph nodes. I loss hearing in right ear temporary. Felt like I was under water. After 5 days I took another flight and I tried to clear my ears and I popped something in my ear and lose hearing temporary. My ear was clogged and bloody. I went to an urgent care center, and they prescribed me amoxicillin. My symptoms were not getting better. When I went to my PCP, he asked me to see an ear and nose doctor. They changed my prescription to doxycycline and prednisone. This cleared my hearing up better, but I still don?t get the feeling that I am completely clear.
5 minutes after receiving vaccine patient suddenly complained of sore throat and became tearful and had slight hoarseness. The symptoms persisted for 5 minutes. No other symptoms were observed. The patient was assessed by Dr. and his pulse oximetry was tested and found to be normal. Patient did not have any difficulty breathing and did not have any swelling of the tongue. 12.5mg of liquid Benadryl was administered. Patient remained in the office and under observation of nurse for and additional 30 minutes after vaccination and went home with mother and was experiencing no further symptoms.
Patient up to date on COVID vaccinations who admitted to hospital for COVID complications twice.  Initially admitted 12/27/21 to  12/29/21 with provider discharge note below:  "Brief Summary of Hospital Stay:  Per HPI, a 90 YO year old male with past medical history of CVA (07/2018), BCC and SCC of the skin, and hypertension. He is presenting to Hospital via EMS with complaint of generalized weakness and GLF. He states he had his covid booster on 12/23, then developed dysgeusia and anorexia approximately 48 hrs prior to arrival. He has some coughing with fluid intake, but denies fevers or chills. His cough is not worsening.  He denies shortness of breath, n/v/d or abdominal pain. Additionally, he had a GLF after turning on the carpet and his foot got stuck. He denies any chest pain, lightheadedness, pre-syncope or LOC.    Initial evaluation in the emergency department demonstrated stable vitals, with exception of hypoxia with ambulation. CBC was unremarkable. CMP demonstrated mild hyperglycemia, mildly elevated BUN, hypoproteinemia, and hypoalbuminemia. Delta troponin was elevated at 10 without significant changes on EKG. He received a full dose aspirin. He will be admitted for treatment and evaluation of generalized weakness.    Hospital Course: 1. Acute respiratory insufficiency: reported desat to 88% w/ ambulation, maintaining adequate O2 sat on RA while at rest. Patient was started on dexamethasone with brisk improvement, no evidence of desaturation with ambulation on RA prior to d/c.   2. Generalized weakness: w/ mechanical GLF at home, suspect due to above.  - PT/OT recommended home with assist, discussed with family, pt to dc home with HC.   3. NSTEMI: likely due to #1. Troponin downtrending - ASA, statin   4. Hx of CVA - ASA, statin   5. BPH - Finasteride, tamsulosin   6. Insomnia - Home trazodone "  Discharge note from second admission on 12/31/21: "Hospital Course: the patient presented with aches, weakness, drooping right eye, dysphagia. He was found to have covid, later developing respiratory failure treated with decadron, remdesivir and lasix, improved to 4 L NC.    MRI negative but suspect MRI negative stroke with sudden onset dysphagia in setting of multiple risk factors and stroke, history of cva. Diet modified, will go to IPR for continued care. Aspirin changed to plavix. Echo unremarkable as was CT imaging of carotids. Telemetry showed normal sinus rhythm . "
vaccine was given after the 30 day beyond use date; No adverse event; vaccine was given after the 30 day beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine was given after the 30 day beyond use date), PRODUCT STORAGE ERROR (vaccine was given after the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) in a 33-year-old male patient who received mRNA-1273 (Spikevax) (batch nos. 052B22A and 059A22A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Aug-2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 07-Sep-2022, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On 07-Sep-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine was given after the 30 day beyond use date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vaccine was given after the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (vaccine was given after the 30 day beyond use date), PRODUCT STORAGE ERROR (vaccine was given after the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (vaccine was given after the 30 day beyond use date) and PRODUCT STORAGE ERROR (vaccine was given after the 30 day beyond use date).    No Concomitant medications were provided.  It was reported that the second dose of the vaccine was given after the 30 day beyond use date. That patient had not reported any symptoms. No additional doses were administered in response at that time. Patient received Monovalent product from Individual vial with vial size of 5.5 mL. Vial was initially stored in the refrigerator on 6 Aug 2022 and did not undergo temperature excursions.  No treatment medications were provided.
Pain at the site of injection; This is a spontaneous report from a contactable other healthcare professional (patient herself). A 40-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EL 3247), via an unspecified route of administration in left arm on 26Jan2021 12:45 PM at single dose for COVID-19 immunization. The patient's medical history included seasonal allergies. The patient had no allergies to medications, food, or other products. Concomitant medications included azelastine hydrochloride/fluticasone propionate (DYMISTA) and cetirizine hydrochloride. The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient has not been tested for COVID-19 since the vaccination. On 26Jan2021 16:00, the patient experienced pain at the site of injection. The event was considered as non-serious by the other healthcare professional. The patient did not receive any treatment for the adverse event. The outcome of the event was recovered on an unspecified date in 2021.
Unprovoked blood clot; PE went to his lung; suffering pains for a week prior; This spontaneous case was reported by a consumer and describes the occurrence of THROMBOSIS (Unprovoked blood clot), PULMONARY EMBOLISM (PE went to his lung) and PAIN (suffering pains for a week prior) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In November 2021, the patient experienced THROMBOSIS (Unprovoked blood clot) (seriousness criteria hospitalization and medically significant), PULMONARY EMBOLISM (PE went to his lung) (seriousness criteria hospitalization and medically significant) and PAIN (suffering pains for a week prior) (seriousness criteria hospitalization and medically significant). The patient was hospitalized on 27-Nov-2021 due to PAIN, PULMONARY EMBOLISM and THROMBOSIS. At the time of the report, THROMBOSIS (Unprovoked blood clot), PULMONARY EMBOLISM (PE went to his lung) and PAIN (suffering pains for a week prior) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication was provided. No concomitant medication information was provided.  COMPANY COMMENT ; This spontaneous case concerns  unknown age of male patient with no medical history reported, who experienced the serious unexpected AESI event of thrombosis, pulmonary embolism and unexpected serious event of pain which occurred on unknown day and dose of mRNA-1273. The patient was hospitalized due to PAIN, PULMONARY EMBOLISM and THROMBOSIS. At the time of report outcome of event is unknown. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns  unknown age of male patient with no medical history reported, who experienced the serious unexpected AESI event of thrombosis, pulmonary embolism and unexpected serious event of pain which occurred on unknown day and dose of mRNA-1273. The patient was hospitalized due to PAIN, PULMONARY EMBOLISM and THROMBOSIS. At the time of report outcome of event is unknown. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.
11:54 am BP 140/100 started amlodipine 3 weeks ago, blood glucose 114, pulse 104 regular.  follow up blood pressure at 12:02pm 126/92, pulse 96 regular.  States feels better.
Reports feeling a little achy the next day but unsure if had encountered a viral infection prior to the vaccine administration. Developed rash to neck, upper chest/back lateral and between breasts
11DEC92 pt c/o rt knee swelling w/fluid prescribed ASA/Ibuprofen; 14DEC92 knees both stiff, no swelling/fluid; bilat wrist stiffened & discomfort on & off; arthralgias in fingers;
UPPER LEFT THIGH FELT (FELT LIKE ITS ASLEEP, BUT NOT  TINGLING AND NO PAIN),  RANGES FROM HER KNEE TO "BUTT AREA" ON THE  SIDE OF THE LEG; THREW UP AT NIGHT; SWEATING; FELT PRETTY BAD; This spontaneous report received from a patient concerned a 19 year old female. The patient's weight was 106 pounds, and height was 61 inches. The patient's concurrent conditions included smoker, and non-alcohol user, and other pre-existing medical conditions included the patient had no known drug or non-drug allergies and had no drug abuse or illicit use. the patient did not have any past medical history and was not receiving any medication. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 201A21A, expiry: UNKNOWN) dose was not reported, administered on 09-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 09-APR-2021, the subject experienced threw up at night. On 09-APR-2021, the subject experienced sweating. On 09-APR-2021, the subject experienced felt pretty bad. On 28-JUL-2021, the subject experienced upper left thigh felt (felt like its asleep, but not tingling and no pain), ranges from her knee to "butt area" on the side of the leg. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from threw up at night, sweating, and felt pretty bad on 10-APR-2021, and had not recovered from upper left thigh felt (felt like its asleep, but not tingling and no pain), ranges from her knee to "butt area" on the side of the leg. This report was non-serious.
Information has been received from a health professional concerning a 2 1/2 year old male who on 10/15/2001 was vaccinated with a dose of varicella vaccine. 30 mins after the injection, on 10/15/2001, the pt developed a wheal 1 1/2 cm in diameter. Additional info has been requested.
Patient presented to the ED for evaluation of bright red blood per rectum on 8/19/2021. He has had intermittent bright red blood in stools since July. Tested positive for COVID on 8/23/2021.
One week after getting the vaccination, site was swollen, red and hot with little blisters in the redness.  Low grade fever occurred several times.
Patient called pharmacy on 11-15-16 and stated she has received Fluvirin PF 2016-2017 0.5 ml IM Deltoid on 11-10-16. On 11-13-16, she notice bumpy rash under the breast. She has used hydrocortisone otc and it has been better.
Chills; This is a spontaneous report from a contactable consumer. This consumer reported similar events for 2 patients. This is 2nd of the two reports. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on an unspecified date (at an unspecified age) as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. On an unspecified date, the patient experienced chills. The clinical outcome of chills was unknown.   same reporter/drug, different patient